CIViC Evidence Items

9 evidence items indexed

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
C	NF1	Mutation	Predictive	Supports	Resistance	Skin Melanoma	Vemurafenib	Whittaker et al., 2013
A	NF1	Mutation	Predictive	Supports	Sensitivity/Response	Plexiform Neurofibroma	Selumetinib	Gross et al., 2020
D	NF1	Mutation	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Sirolimus,Mirdametinib	Maertens et al., 2013
D	NF1	Loss	Predictive	Supports	Sensitivity/Response	Malignant Peripheral Nerve Sheath Tumor	JQ1 Compound	Patel et al., 2014
A	NF1	Mutation	Predictive	Supports	Sensitivity/Response	Plexiform Neurofibroma	Selumetinib	Dombi et al., 2016
B	NF1	Mutation	Predictive	Supports	Sensitivity/Response	Childhood Low-grade Glioma	Selumetinib	Fangusaro et al., 2019
B	NF1	Mutation OR GNA11 Q209L	Predictive	Does Not Support	Sensitivity/Response	Cancer	Trametinib	Wisinski et al., 2023
D	NF1	Mutation	Predictive	Supports	Resistance	Skin Melanoma	Vemurafenib	Maertens et al., 2013
D	NF1	Mutation	Predictive	Supports	Sensitivity/Response	Skin Melanoma	VTX-11e,AZ628	Whittaker et al., 2013